Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13106459 | 0.86 | HTT (0.36) | HTTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL27872993 | 0.85 | CYP1A2 (0.38) | HTTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL20450508 | 0.85 | LMNA (0.38) | HTTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22164596 | 0.82 | LMNA (0.39) | HTTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30620821 | 0.80 | HTT (0.36) | HTTRXFP1ALDH1A1CASP3NPSR1 | |
| SCHEMBL21958437 | 0.79 | ESR1 (0.42) | HTTALDH1A1CHRM4KDM4EHPGD | |
| SCHEMBL13106212 | 0.79 | HTT (0.38) | HTTALDH1A1CASP3CHRM4MAPT | |
| SCHEMBL13106417 | 0.79 | CHRM4 (0.42) | HTTCYP1A2CYP2C9CYP2C19CHRM4 | |
| SCHEMBL1047655 | 0.77 | ALDH1A1 (0.36) | HTTALDH1A1CASP3LMNASMN1; SMN2 | |
| SCHEMBL13106339 | 0.77 | CASP3 (0.48) | HTTCYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214988-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2025-07-03 | — | — | US | disclosed |
| US-12077534-B2 | Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | LES LABORATOIRES SERVIER (FR) | 2024-09-03 | — | — | US | disclosed |
| CN-113454085-B | AZA heterobicyclic inhibitors of MAT2A and methods for treating cancer | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| EP-3902803-B1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | SERVIER LAB (FR) | 2023-02-01 | — | — | EP | disclosed |
| EP-3902803-B1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | SERVIER LAB (FR) | 2023-02-01 | — | — | EP | disclosed |
| US-20220144820-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2022-05-12 | — | — | US | disclosed |
| EP-3902803-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | Les Laboratoires Servier SAS (FR) | 2021-11-03 | — | — | EP | disclosed |
| CN-113454085-A | AZA heterobicyclic inhibitors of MAT2A and methods for treating cancer | 法国施维雅药厂 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020139991-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020139991-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| EP-3269715-B1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-20080194661-A1 | Antifungal Triazole Derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077534-B2 | Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | MAT2A, MAT2B, MAT1A | HTT 3638/4885CYP1A2 509/4885CYP2D6 643/4885 |
| US-20220144820-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | HTT 3638/4885CYP1A2 509/4885CYP2D6 643/4885 |
| US-20250214988-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | HTT 3255/4885CYP1A2 907/4885CYP2D6 788/4885 |
| US-20080194661-A1 | Antifungal Triazole Derivatives | ERG28, CYP51A1, CYP3A43 | HTT 2323/4885CYP1A2 15/4885CYP2D6 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.